Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 07, 2015 12:17 AM ET


Company Overview of Dr. Reddy's Laboratories Ltd.

Company Overview

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordanc...

8-2-337, Road No. 3

Banjara Hills

Hyderabad,  500034


Founded in 1984

20,373 Employees


91 40 4900 2900


91 40 4900 2999

Key Executives for Dr. Reddy's Laboratories Ltd.

Co-Chairman, Chief Executive Officer, Managing Director, Member of the Management Council, Member of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Age: 55
Total Annual Compensation: $6.3M
Chairman of The Board, Member of The Management Council, Chairman of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Age: 48
Total Annual Compensation: $6.3M
Compensation as of Fiscal Year 2015.

Dr. Reddy's Laboratories Ltd. Key Developments

Dr. Reddy's Laboratories Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

Dr. Reddy's Laboratories announced that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM (esomeprazole magnesium) Delayed-Release Capsules in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA). The NEXIUM (esomeprazole magnesium) Delayed-Release Capsules brand and generic had U.S. sales of approximately $5.2 Billion MAT for the most recent twelve months ending in July 2015 according to IMS Health. Dr. Reddy’s ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg are available in bottle count size of 30.

Dr. Reddy's Laboratories Ltd. Approves Adoption of New Articles of Association

Dr. Reddy's Laboratories Ltd. announced that the shareholders of the company approved the adoption of new articles of association of the company through the postal ballot.

BioMarin Pharmaceutical Inc. Enters into a Settlement Agreement with Dr. Reddy's Laboratories, Inc

BioMarin Pharmaceutical Inc. announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories Inc. that resolves patent litigation in the United States (U.S.) related to BioMarin's Kuvan (sapropterin dihydrochloride) 100mg oral tablets. Under the terms of the settlement, BioMarin will grant Dr. Reddy's a non-exclusive license to its patents related to Kuvan to allow Dr. Reddy to market a generic version of sapropterin dihydrochloride 100mg tablets in the U.S. for the indications approved for Kuvan beginning at a confidential date in the future, but which is more than five years from September 18, 2015, or earlier under certain circumstances. Additional details of the agreement remain confidential. BioMarin continues to vigorously enforce its intellectual property related to Kuvan. This includes continuing its suit against Par Pharmaceutical Inc., which is not affected by this settlement. As required by law, BioMarin and Dr. Reddy will submit the Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice.

Similar Private Companies By Industry

Company Name Region
Universal Medicare Pvt. Ltd. Asia
Wyeth Limited Asia
Avinash Drugs Ltd. Asia
Indian Drugs & Pharmaceuticals Ltd. Asia
Bristol-Myers Squibb India Pvt. Ltd. Asia

Recent Private Companies Transactions

September 25, 2015
Alchemia Limited, Worldwide Exclusive Intellectual Property Rights of Fondaparinux Sodium
April 1, 2015
UCB India Private Limited, Portfolio of Established Product Business
November 14, 2014
Cherokee Pharma, LLC

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dr. Reddys Laboratories Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at